In today’s Pharmaceutical Executive Daily, the FDA approves an expanded indication for Palynziq in patients aged 12 and older ...

A key advantage of using RWD in a natural history study is gaining diverse and representative data. RWD covers broad patient populations, including those with comorbidities, various age groups, and ...

In today’s Pharmaceutical Executive Daily, the FDA approves Hernexeos under a national priority voucher program, industry ...

The approval comes under the National Priority Voucher Program, joining Augmentin XR as one of the few approvals from the voucher program as of February 27, 2026. Hernexeos was granted a national ...

Significant PrEP underutilization remains, with ~600,000 US users versus an estimated 2.2 million who could benefit, largely due to low awareness, stigma, and misconceptions about HIV risk. Yeztugo is ...

Joseph Kleiman, president of Buzz Health, discusses the impact of Trump RX on transparency in drug pricing. In his ...

This episode of The Ron Lanton Report examines whether healthcare consolidation in the United States may be approaching a ...

In today’s Pharmaceutical Executive Daily, Alkermes outlines its CEO succession plan following Richard Pops’ retirement announcement, leadership changes continue at Sarepta Therapeutics and Rivus ...

Boehringer Ingelheim acquires an exclusive license for a preclinical oral immunology program from Sitryx in a deal worth over ...

Sarepta Therapeutics begins a CEO succession process, while Rivus Pharmaceuticals appoints a new chief executive to advance its late-stage pipeline in MASH, obesity, and cardiometabolic disease.

Alkermes announces that longtime CEO Richard Pops plans to step down on July 31, 2026, with his successor already set to step ...